Stockscreener 앱 받기
5.24
0.19%
-0.010
시간 외 거래:
5.28
0.04
+0.76%
전일 마감가:
$5.25
열려 있는:
$5.26
하루 거래량:
761.25K
Relative Volume:
0.83
시가총액:
$339.01M
수익:
$500
순이익/손실:
$-56.02M
주가수익비율:
-3.7941
EPS:
-1.3811
순현금흐름:
$-45.49M
1주 성능:
-14.52%
1개월 성능:
+7.38%
6개월 성능:
-18.25%
1년 성능:
+340.34%
1일 변동 폭
$5.16
$5.3825
1주일 범위
$5.16
$6.22
52주 변동 폭
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.24 | 338.37M | 500 | -56.02M | -45.49M | -1.3811 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Leerink Partners | Outperform |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Immuneering brings 55-patient pancreatic survival update to ASCO oral - Stock Titan
Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification - Stock Titan
Immuneering (IMRX) Reveals Promising Genetic Data at Upcoming AA - GuruFocus
Immuneering presents genetic data on atebimetinib resistance - Investing.com
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - The Manila Times
In 123 patients, Immuneering's cancer drug showed rare resistance signals - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears - Yahoo Finance
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Needham healthcare fireside chat adds Immuneering CEO on April 13 - Stock Titan
Immuneering CorporationClass A Common Stock (NQ: IMRX - The Chronicle-Journal
Immuneering Corp Stock: Precision Oncology Innovator with Deep Pipeline Potential for North American - AD HOC NEWS
Bull Bear: Can Immuneering Corporation scale operations efficiently2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Immuneering Corp Stock (ISIN: US45255L1089) Faces Short-Term Pressure Amid Clinical Momentum and Ana - AD HOC NEWS
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - The Manila Times
Immuneering Corp (IMRX) CPO acquires shares through employee stock plan - Stock Titan
New MEK approach in 64 cancer patients shows fewer resistance mutations - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com
Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat
Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com
Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat
Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corporation Reports 64% Overall Survival in Phase 2a Trial for First-Line Pancreatic Cancer and Outlines 2026 Development Plans - Quiver Quantitative
Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times
Late-stage cancer firm Immuneering to outline pipeline at Miami investor event - Stock Titan
IMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Yahoo Finance
IMRX Should I Buy - Intellectia AI
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Merger Talk: Does Immuneering Corporation outperform in volatile marketsJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn
Investment Report: Does Immuneering Corporation meet Warren Buffetts criteriaPortfolio Update Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Immuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Oncology company Immuneering to detail pipeline, strategy at virtual Oppenheimer event - Stock Titan
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru
Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus
Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World
Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat
Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia
Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat
Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immuneering Corp 주식 (IMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schall Thomas J. | Director |
Jan 15 '26 |
Buy |
4.67 |
21,645 |
101,041 |
74,530 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jan 15 '26 |
Buy |
4.57 |
2,298 |
10,502 |
376,496 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jan 13 '26 |
Buy |
4.15 |
2,626 |
10,906 |
25,970 |
| Feinberg Peter | Director |
Jan 12 '26 |
Buy |
4.35 |
20,000 |
86,904 |
135,441 |
| Feinberg Peter | Director |
Oct 03 '25 |
Buy |
6.67 |
7,500 |
50,025 |
156,766 |
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
| Feinberg Peter | Director |
Sep 30 '25 |
Buy |
7.03 |
7,500 |
52,730 |
149,266 |
| Feinberg Peter | Director |
Sep 29 '25 |
Buy |
7.18 |
5,000 |
35,900 |
141,766 |
3.67%
자본화:
|
볼륨(24시간):